RSV Antiviral Pipeline: Pediatric & High-Risk Adults — PatSnap Eureka
RSV Antiviral Pipeline: Pediatric & High-Risk Adult Populations
RSV causes approximately 3 million hospitalizations and 120,000 pediatric deaths annually. Approved options remain critically limited. Explore the full modality landscape — from next-generation monoclonal antibodies to allosteric polymerase inhibitors — powered by PatSnap Eureka patent and literature intelligence.
A Decades-Old Unmet Need in RSV Prevention & Treatment
Respiratory syncytial virus (RSV) is a single-serotype, negative-sense RNA virus within the Pneumoviridae family, classified into two major antigenic subtypes — RSV-A and RSV-B — and multiple genotypes that co-circulate seasonally and differ in virulence. According to WHO, RSV is the leading global cause of acute lower respiratory tract infections in infants, young children, and high-risk adults. The primary at-risk populations include preterm infants, infants with congenital heart disease (CHD) or chronic lung disease of prematurity (CLD), children under 2 years of age, adults over 65 years, and immunocompromised individuals including hematology-oncology patients.
Despite more than six decades of research, approved intervention options remain critically limited — confined primarily to palivizumab for prophylaxis in select high-risk pediatric subgroups and ribavirin for a narrow set of complicated cases. The NIH and CDC continue to prioritize RSV as a major public health challenge. This treatment gap drives an expansive innovation landscape spanning six distinct therapeutic modalities, as documented in patent filings and academic literature retrieved via PatSnap's global innovation intelligence platform.
The RSV fusion (F) protein is the dominant therapeutic target across the entire dataset, appearing across dozens of retrieved results. The pre-fusion (pre-F) conformation is strongly emphasized as superior for eliciting potent neutralizing antibodies — including those targeting antigenic Site II, Site Ø (pre-F specific), and the p27 domain. FDA Center for Biologics Evaluation and Research researchers identified that peptides spanning the F-p27 domain sequence significantly reduced viral loads and lung pathology in vaccinated animals, expanding the understood protective epitope space beyond conventional Site II targeting.
RSV Pipeline: Key Agents by Modality & Development Stage
Derived from patent filings and academic literature retrieved via PatSnap Eureka. Development stages reflect signals at time of publication in the dataset.
| Agent / Platform | Modality | Primary Target | Developer | Stage | Key Population |
|---|---|---|---|---|---|
| Palivizumab (Synagis) | Monoclonal Antibody | RSV F protein — Site II | MedImmune/AstraZeneca | Approved | High-risk pediatric (≤35 wk GA, CHD, BPD) |
| MEDI8897 (nirsevimab) | Monoclonal Antibody | RSV F protein — pre-F | MedImmune/AstraZeneca | Phase 1 | All infants (single-dose prophylaxis) |
| EDP-938 | Small Molecule — N inhibitor | RSV nucleoprotein (N) | Enanta Pharmaceuticals | Phase 2 | Adults; pediatric potential |
| ALX-0171 | Nanobody (trivalent) | RSV F protein | Ablynx (Sanofi) | Preclinical | Pediatric — inhaled delivery |
| PC786 | Small Molecule — L-protein inhibitor | RdRp/L-protein complex | Pulmocide Limited | Preclinical | Adults — inhaled delivery |
| RSV/ΔNS2/Δ1313/I1314L | Live-Attenuated Vaccine | RSV replication (NS2 deletion) | NIH / NIAID | Phase 1 | RSV-seronegative children |
| Novavax RSV F Nanoparticle | Subunit Vaccine | RSV F protein (recombinant) | Novavax, Inc. | Phase 1/2 | Adults ≥60 years; maternal |
| GD-mAb | Monoclonal Antibody | RSV G glycoprotein | Academic (phage display) | Preclinical | Broad — pediatric/adult |
| Allosteric RdRp Inhibitor Scaffold | Small Molecule — RdRp allosteric | RSV L-protein (elongation) | Georgia State University | Discovery | Broad |
| PanAd3-RSV / MVA-RSV | Vector-Based Vaccine | RSV F, N, M2-1 proteins | ReiThera / Keires | Preclinical | Broad — mucosal delivery |
Need deeper competitive intelligence on RSV assignees?
PatSnap Eureka maps innovation activity across pharma, biotech, academic, and government sources in one searchable platform.
Six Distinct Approaches to RSV Intervention
Patent filings and academic literature in the PatSnap Eureka dataset document six therapeutic modality clusters, each targeting different stages of the RSV replication cycle or host immune response.
Passive Immunoprophylaxis: Monoclonal Antibodies
The most extensively documented modality in the dataset. Palivizumab (Synagis) — a humanized murine IgG1 mAb targeting RSV F protein Site II — is the only currently approved RSV-specific intervention, limited to high-risk pediatric subgroups and requiring 5 monthly intramuscular injections per season. MEDI8897 (nirsevimab) introduces a YTE Fc mutation extending serum half-life, enabling a single-dose prophylaxis regimen for all infants. A Phase 1 study in 136 adults (102 active, 34 placebo) at doses of 300–3,000 mg demonstrated acceptable safety and pharmacokinetics. ALX-0171, a trivalent Nanobody, reduced apically released RSV titers to near or below the limit of detection at 900 mM within 24 hours post-infection in pediatric bronchial epithelial cells, outperforming palivizumab in the therapeutic setting.
Most advanced: MEDI8897 Phase 1 → broad infant prophylaxisSmall-Molecule Replication Inhibitors
Three mechanistic subclasses are documented. Fusion inhibitors (GS5806/presatovir, ziresovir, BMS433771) target the F protein conformational change — a cross-resistance study identified the K394R mutation as conferring resistance across this class. EDP-938 (Enanta Pharmaceuticals), a nucleoprotein inhibitor with EC50 values of 21–64 nM in primary human bronchial epithelial cells (HBECs), demonstrated oral bioavailability in African green monkeys and reached Phase 2. EDP-938 has a higher barrier to resistance than fusion inhibitors, with no observed cross-resistance between classes. PC786 (Pulmocide), an inhaled L-protein inhibitor, reduced viral RNA and infectious particles in air-liquid interface models initiated 3 days post-infection. A Georgia State University allosteric RdRp inhibitor scaffold from a 57,000-compound HTS blocks RNA elongation post-initiation.
Most advanced: EDP-938 Phase 2 (Enanta Pharmaceuticals)Vaccine Platforms
The most diverse modality in the dataset. Novavax RSV F nanoparticle vaccine (60 or 90 µg ± aluminum phosphate) demonstrated acceptable safety and rapid immunogenic responses in adults ≥60 years when co-administered with inactivated trivalent influenza vaccine. In a double-blind RCT, maternal RSV vaccination reduced infant antimicrobial prescribing by 12.9% over the first 3 months of life. Janssen Vaccines & Prevention filed two pending IL-jurisdiction patents describing an adenoviral vector + recombinant pre-F protein prime-boost strategy. NIH/NIAID conducted a Phase 1 pediatric trial of RSV/ΔNS2/Δ1313/I1314L — a live-attenuated candidate with NS2 gene deletion — confirming 10⁶ PFU dose immunogenicity in RSV-seronegative children. Inovio Pharmaceuticals is identified as a DNA/mRNA vaccine assignee in the dataset. The PatSnap life sciences platform tracks all active vaccine patent filings in this space.
Most advanced: Novavax Phase 1/2 adults ≥60; NIH Phase 1 pediatricGene Therapy-Based Antibody Delivery
Two preclinical approaches use viral vectors to achieve sustained in vivo palivizumab production. Recombinant AAV2/8 and lentiviral vector (rSIV.F/HN) delivery of palivizumab-encoding transgenes in murine models provided complete protection from RSV-induced weight loss when administered 28 days prior to challenge. A Weill Medical College of Cornell University adenoviral approach targeting RSV F glycoprotein neutralizing epitopes achieved long-term protection, circumventing the 30-day re-dosing requirement of conventional palivizumab. Both approaches remain at preclinical stage in murine models, representing a long-term durability strategy for high-risk populations where repeated dosing is impractical.
Stage: Preclinical (murine models)Host-Defense Peptides & Innate Immune Modulators
The human cathelicidin LL-37, studied at the University of Edinburgh, directly damages the RSV viral envelope, disrupts viral particles, and decreases virus binding to human epithelial cells in vitro. Its antiviral effect was retained by a truncated central peptide fragment. Specialized pro-resolving mediators (SPMs) PCTR1 and protectin D1 (PD1), administered intranasally post-RSV infection in mice, reduced genomic viral load, eosinophils, neutrophils, and NK cells in the lung. PCTR1 additionally increased cathelicidin expression, suggesting convergence with the LL-37 axis. OM-85 (oral standardized bacterial lysate) demonstrated complete protection at 1 mg dose given intranasally four times in BALB/c mice, with dose- and time-dependent inhibition of viral replication and reduced peribronchial lung inflammation.
Stage: All preclinical — novel host-directed mechanismsNucleic Acid & Oligonucleotide-Based Approaches
Two independent Stockholm University groups identified antiviral activity of non-coding oligonucleotides. Synthetic single-stranded DNA oligonucleotides (25–40 nucleotides) inhibited RSV infection in vitro in a length-dependent manner by competing with virus for nucleolin receptor binding — establishing nucleolin as an exploitable host-side RSV entry receptor. Separately, naturally occurring small non-coding RNA fragments — including YRNA-, tRNA-, and rRNA-derived species from human bronchoalveolar lavage fluid — demonstrated antiviral activity against RSV in GFP-expressing RSV reporter assays. Alnylam Pharmaceuticals is identified in the dataset through their work maintaining the RSV Memphis-37 human challenge model, signaling therapeutic development infrastructure interest. The PatSnap analytics platform supports landscape mapping of nucleic acid-based IP.
Stage: Preclinical/discovery — novel nucleolin entry mechanismRSV Pipeline: Key Data Visualizations
Quantitative signals extracted from patent and literature records in the PatSnap Eureka RSV dataset, illustrating development stage distribution and antiviral potency benchmarks.
RSV Pipeline Agents by Development Stage
Distribution of all RSV agents in the dataset across development stages, from approved to discovery — highlighting the significant preclinical-stage opportunity.
EDP-938 In Vitro Potency: EC50 Range in Primary HBECs
EDP-938 EC50 values of 21–64 nM across RSV-A and RSV-B strains in primary human bronchial epithelial cells, with higher barrier to resistance than fusion inhibitors.
RSV Innovation by Assignee Type in Dataset
Distribution of innovation activity across pharma/biotech (patent-driven) and academic/government (literature-driven) sources in the retrieved dataset.
Top RSV Clinical Translation Signals by Advancement
The four clearest clinical translation signals in the dataset, ranked by development stage advancement as of publication dates in retrieved results.
Key RSV Molecular Targets & Mechanistic Findings
Mechanistic insights from patent and literature records in the PatSnap Eureka dataset, spanning viral proteins, host receptors, and innate immune axes.
RSV F Protein — Pre-Fusion Conformation
The dominant target across the entire dataset. Pre-F exposes Site Ø and maintains Site II in a higher-affinity configuration for neutralizing antibodies. The p27 domain — present only in the unprocessed F0 precursor — was identified by FDA researchers as capable of reducing viral loads in animals without conventional in vitro neutralization, potentially reflecting Fc-mediated or T cell-mediated mechanisms beyond simple neutralization. Janssen patent filings describe adenoviral vector encoding of stabilized pre-F for a prime-boost vaccine strategy. Track pre-F patent claims via PatSnap Analytics.
RSV Nucleoprotein (N) — Post-Entry Replication Block
EDP-938 binds the nucleoprotein N and blocks post-entry replication at a mechanistically distinct step from fusion inhibitors and non-nucleoside L polymerase inhibitors. In vitro resistance profiling demonstrated a higher barrier to resistance for EDP-938 than for either fusion inhibitors or RdRp inhibitors, with no observed cross-resistance between EDP-938 and those classes — supporting its use in combination antiviral strategies for high-risk adult and pediatric populations.
RdRp / L-Protein Complex — Allosteric Elongation Inhibition
The L-protein is the enzymatic core of the viral RNA replication machinery. PC786 (Pulmocide), delivered as an inhaled formulation, reduced both viral RNA and infectious particles in air-liquid interface human airway epithelium models when initiated 3 days post-infection at peak viral load — demonstrating treatment (not just prophylactic) utility. An allosteric inhibitor scaffold from a 57,000-compound Georgia State University high-throughput screen blocks RNA elongation after initial 3-nucleotide extension, a mechanism distinct from nucleoside analog incorporation strategies.
RSV G Protein CCR — Combination Immunotherapy Target
The RSV G glycoprotein central conserved region (CCR) is targeted by monoclonal antibodies 130-6D and 131-2G. Combination therapy using both mAbs targeting overlapping G protein CCR epitopes significantly decreased RSV-associated pulmonary inflammation in mice compared to either antibody alone, establishing the CCR as a viable combination immunotherapy target mechanistically distinct from F protein-targeting approaches. GD-mAb, a fully humanized phage-display-derived mAb targeting RSV G, demonstrated high binding affinity (KD = 3.13 ± 0.89 nM) and concentration-dependent plaque reduction in preclinical models.
Who Is Driving RSV Innovation?
Innovation activity in the retrieved dataset is distributed across pharmaceutical industry, biotech, academic institutions, and government/public health agencies — a mix of patent-driven commercial IP and literature-driven academic research. The most recent commercial patent signal in the dataset is from Janssen Vaccines & Prevention B.V. (Johnson & Johnson subsidiary), with two pending IL-jurisdiction patents on adenoviral vector + pre-F protein prime-boost vaccine combinations filed in 2023. Sanofi Pasteur Inc. holds one pending BR-jurisdiction patent with a 2025 filing date on RSV vaccination methods.
Enanta Pharmaceuticals represents the most clinically advanced small-molecule signal (EDP-938 at Phase 2) in the dataset, documented through academic literature rather than retrieved patents. MedImmune (AstraZeneca) contributes the MEDI8897 Phase 1 clinical study publication. Novavax provides nanoparticle RSV F vaccine Phase 1/2 data in older adults and maternal vaccination trial data. Ablynx (now part of Sanofi) contributes ALX-0171 Nanobody preclinical data.
On the academic and government side, NIH/NIAID conducted both the live-attenuated vaccine Phase 1 pediatric trial and RSV G protein mAb combination therapy preclinical studies. The FDA Center for Biologics Evaluation and Research contributed F protein protective epitope mapping including the p27 domain findings. The University of Edinburgh MRC Centre leads cathelicidin LL-37 antiviral mechanism research. PatSnap customers in pharma and biotech use Eureka to monitor exactly this kind of distributed innovation landscape. The full PatSnap Analytics platform supports deep assignee benchmarking and competitive IP mapping.
RSV Antiviral Pipeline — Key Questions Answered
The RSV fusion (F) protein is the dominant therapeutic target in the dataset, appearing across dozens of retrieved results. The pre-fusion (pre-F) conformation is strongly emphasized as superior for eliciting potent neutralizing antibodies, including those targeting antigenic Site II, Site Ø (pre-F specific), and the p27 domain.
MEDI8897 (nirsevimab), developed by MedImmune/AstraZeneca, is a next-generation recombinant human RSV mAb with a modified Fc region (YTE mutation) that extends serum half-life, enabling a single-dose prophylaxis regimen for all infants rather than only high-risk subgroups. Palivizumab requires 5 monthly intramuscular injections per RSV season and is limited to high-risk pediatric subgroups.
EDP-938 (Enanta Pharmaceuticals), a nucleoprotein inhibitor, reached Phase 2 clinical trial status as reported in 2019–2021 publications. In vitro EC50 values of 21–64 nM were reported across RSV-A and RSV-B strains in primary human bronchial epithelial cells, and non-human primate data demonstrated oral bioavailability and in vivo efficacy in the African green monkey challenge model.
ALX-0171, a trivalent Nanobody targeting the RSV F protein, at 900 mM reduced apically released RSV titers to near or below the limit of detection within 24 hours at 24 hours post-infection in well-differentiated primary pediatric bronchial epithelial cell cultures infected with clinical RSV isolates, outperforming palivizumab in the therapeutic (post-infection) setting. In newborn lambs, inhaled ALX-0171 delivered by daily nebulization for 3–5 days post-infection significantly reduced viral loads and clinical disease.
Novavax-affiliated research demonstrated that maternal RSV vaccination reduced antimicrobial prescribing among infants by 12.9% over the first 3 months of life in a double-blind, randomized, placebo-controlled trial, linking RSV prevention to antimicrobial stewardship outcomes.
Host-directed approaches include cathelicidin LL-37, which directly damages the RSV viral envelope and disrupts viral particles; specialized pro-resolving mediators (SPMs) PCTR1 and protectin D1 (PD1), which administered intranasally post-RSV infection in mice reduced genomic viral load, eosinophils, neutrophils, and NK cells in the lung; and OM-85 oral standardized bacterial lysate, which demonstrated dose- and time-dependent inhibition of viral replication with complete protection achieved at 1 mg dose given intranasally four times. All are at preclinical stage.
Still have questions about the RSV pipeline? Let PatSnap Eureka answer them instantly.
Ask Eureka About RSV AntiviralsAccelerate Your RSV Drug Discovery & Competitive Intelligence
Join 18,000+ innovators already using PatSnap Eureka to monitor RSV patent filings, track pipeline agents, and identify emerging therapeutic targets across pediatric and high-risk adult populations.
References
- Protective antigenic sites identified in RSV fusion protein reveals importance of p27 domain — FDA Center for Biologics Evaluation and Research
- Combination Therapy Using Monoclonal Antibodies against RSV G Glycoprotein Protects from RSV Disease in BALB/c Mice — NIH/NIAID
- EDP-938, a novel nucleoprotein inhibitor of RSV, demonstrates potent antiviral activities in vitro and in a non-human primate model — Enanta Pharmaceuticals
- Late therapeutic intervention with RSV L-protein polymerase inhibitor PC786 — Pulmocide Limited
- Development of an allosteric inhibitor class blocking RNA elongation by the RSV polymerase complex — Georgia State University
- Single-Stranded Oligonucleotide-Mediated Inhibition of Respiratory Syncytial Virus Infection — Stockholm University
- Safety, Tolerability, and Pharmacokinetics of MEDI8897 (nirsevimab), the RSV Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults — MedImmune/AstraZeneca
- Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures — Ablynx
- Delivery of ALX-0171 by inhalation greatly reduces RSV disease in newborn lambs — Ablynx
- Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against RSV — Academic (phage display)
- Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in RSV Fusion Protein
- Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938 — Enanta Pharmaceuticals
- Evaluation of Small Molecule Combinations against RSV In Vitro — MacSynergy II analysis
- Lentiviral and AAV-mediated Expression of Palivizumab Offer Protection against RSV Infection — Gene therapy preclinical
- Genetic Delivery of an Anti-RSV Antibody Protects Against Pulmonary Infection with RSV in Mice — Weill Medical College of Cornell University
- Immunogenicity and Safety of a RSV Fusion Protein Nanoparticle Vaccine in Older Adults — Novavax, Inc.
- Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates — ReiThera/Keires
- Safety and Immunogenicity of the RSV Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children — NIH/NIAID Phase 1
- Prevention of antimicrobial prescribing among infants following maternal vaccination against RSV — Novavax maternal RCT
- Cathelicidins Have Direct Antiviral Activity against RSV In Vitro and Protective Function In Vivo in Mice and Humans — University of Edinburgh
- Protectins PCTR1 and PD1 Reduce Viral Load and Lung Inflammation During RSV Infection in Mice — Brigham and Women's Hospital/Harvard
- Airway Administration of Bacterial Lysate OM-85 Protects Mice Against RSV Infection — PUCRS Brazil
- Inhibition of RSV Infection by Small Non-Coding RNA Fragments — Stockholm University
- World Health Organization (WHO) — RSV global disease burden data
- National Institutes of Health (NIH) — RSV research and public health resources
- Centers for Disease Control and Prevention (CDC) — RSV surveillance and epidemiology
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full clinical pipeline or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.